<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci</journal-id>
<journal-id journal-id-type="hwp">jneuro</journal-id>
<journal-id journal-id-type="pmc">jneurosci</journal-id>
<journal-id journal-id-type="publisher-id">J. Neurosci</journal-id>
<journal-title-group>
<journal-title>The Journal of Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0270-6474</issn>
<issn pub-type="epub">1529-2401</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30952813</article-id>
<article-id pub-id-type="pmc">6561688</article-id>
<article-id pub-id-type="publisher-id">2041-18</article-id>
<article-id pub-id-type="doi">10.1523/JNEUROSCI.2041-18.2019</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
<subj-group>
<subject>Neurobiology of Disease</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yennawar</surname>
<given-names>Madhumita</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-9645-057X</contrib-id>
<name>
<surname>White</surname>
<given-names>Rachel S.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-7844-5518</contrib-id>
<name>
<surname>Jensen</surname>
<given-names>Frances E.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Department of Systems Pharmacology and Translational Therapeutics, and </aff>
<aff id="aff2"><sup>2</sup>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence should be addressed to Frances E. Jensen at <email>frances.jensen@uphs.upenn.edu</email></corresp>
<fn fn-type="con">
<p>Author contributions: M.Y. and F.E.J. designed research; M.Y. and R.S.W. performed research; M.Y. analyzed data; M.Y. wrote the first draft of the paper; M.Y., R.S.W., and F.E.J. edited the paper; M.Y. and F.E.J. wrote the paper; F.E.J. contributed unpublished reagents/analytic tools.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>12</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>12</day>
<month>12</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>39</volume>
<issue>24</issue>
<fpage>4814</fpage>
<lpage>4828</lpage>
<history>
<date date-type="received">
<day>9</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>13</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 the authors</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="zns02419004814.pdf"></self-uri>
<abstract>
<p>Pathogenic mutations in cyclin-dependent kinase-like 5 (<italic>CDKL5</italic>) result in CDKL5 deficiency disorder (CDD), a rare disease marked by early-life seizures, autistic behaviors, and intellectual disability. Although mouse models of CDD exhibit dendritic instability and alterations in synaptic scaffolding proteins, studies of glutamate receptor levels and function are limited. Here we used a novel mouse model of CDD, the <italic>Cdkl5<sup>R59X</sup></italic> knock-in mouse (R59X), to investigate changes in synaptic glutamate receptor subunits and functional consequences. Male mice were used for all experiments to avoid the confounding effects of X-inactivation that would be present in female heterozygous mice. We showed that adult male R59X mice recapitulated the behavioral outcomes observed in other mouse models of CDD, including social deficits and memory and learning impairments, and exhibited decreased latency to seizure upon pentylenetetrazol administration. Furthermore, we observed a specific increase in GluA2-lacking α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptors (AMPARs) in the adult R59X hippocampus, which is accompanied electrophysiologically by increased rectification ratio of AMPAR EPSCs and elevated early-phase long term potentiation (LTP). Finally, we showed that acute treatment with the GluA2-lacking AMPAR blocker IEM-1460 decreased AMPAR currents, and rescued social deficits, working memory impairments, and seizure behavior latency in R59X mice.</p>
<p><bold>SIGNIFICANCE STATEMENT</bold> CDKL5 deficiency disorder (CDD) is a rare disease marked by autistic-like behaviors, intellectual disability, and seizures. While synaptic dysfunction has been observed in mouse models of CDD, there is limited information on how synaptic alterations contribute to behavioral and functional changes in CDD. Here we reveal elevated hippocampal GluA2-lacking AMPAR expression in a novel mouse model of CDD that is accompanied by changes in synaptic AMPAR function and plasticity. We also show, for the first time, that acutely targeting GluA2-lacking AMPAR dysregulation rescues core synaptic and neurobehavioral deficits in CDD.</p>
</abstract>
<kwd-group>
<kwd>autism</kwd>
<kwd>behavior</kwd>
<kwd>CDKL5</kwd>
<kwd>excitability</kwd>
<kwd>learning and memory</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>